Literature DB >> 7905204

Ligation of leukocyte function-associated (LFA) molecule-1 provides an accessory signal for T-cell activation with pokeweed mitogen.

G Wallays1, J L Ceuppens.   

Abstract

The ligation between leucocyte-Function-Associated Molecule 1 (LFA-1) and Intercellular Adhesion Molecules (ICAM) is thought to be an important component in the stimulatory interaction between antigen-presenting cells (APC) and T cells. Similar to antigenic stimulation, T-cell stimulation with pokeweed mitogen (PWM) is highly dependent on monocytes as accessory cells. This is partly a consequence of the requirement for mitogen presentation by the monocytes. The study described here addressed the question of whether LFA-1 ligation by accessory cells influences the activation of T cells with PWM. To avoid multiple costimulatory interactions between T cells and monocytes, experiments were performed with purified T cells, which were stimulated with PWM bound on autologous red blood cells (PWM-RBC). Binding on the RBC substituted partly for PWM presentation by the monocytes. Anti-LFA-1 MoAbs were presented in the immobilized form in order to mimick LFA-1 ligation by cell-bound ICAM. Three out of three different MoAbs against the beta-chain of the LFA-1 molecule (CD18) and two out of three MoAbs against the alpha-chain (CD11a) had an enhancing effect on T-cell proliferation. Proliferation was increased further by simultaneous addition of interleukin (IL)-1 beta and IL-6. Ligation of the LFA-1 molecule was found to enhance IL-2 production and tumour necrosis factor-alpha (TNF-alpha) production. The results suggest that interaction of LFA-1 with ICAM on the monocytes contributes to the accessory signal activity of monocytes in T-cell activation with PWM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905204     DOI: 10.1111/j.1365-3083.1994.tb03352.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

2.  Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial.

Authors:  Carlos J Montoya; Fabian Jaimes; Edwin A Higuita; Sandra Convers-Páez; Santiago Estrada; Francisco Gutierrez; Pedro Amariles; Newar Giraldo; Cristina Peñaloza; Maria T Rugeles
Journal:  Trials       Date:  2009-06-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.